Tags : BI-1206

BioInvent Reports the Enrollment of First Patient in P-I/IIa Study

Shots: The focus of the study is to evaluate safety and tolerability profile of the combination of BI-1206 with Keytruda, characterizing PK/PD profile and to determine the recommended dose of the combination regimen The study is divided into two parts into Part A, a dose escalation of BI-1206 in combination with the standard dose of […]Read More

BioInvent Collaborates with MSD to Evaluate BI-1206 in Combination with

Shots: The companies collaborate to evaluate the combination of BioInvent’s BI-1206 and MSD’s Keytruda in a P-l/lla clinical study for patients with solid tumors, prior treated with anti-PD-1 or anti-PD-L1 Ab The collaboration allows BioInvent to expand the clinical development of BI-1206 against solid tumors. The preclinical data demonstrated that BI-1206 addresses the mechanism of […]Read More

BioInvent to Initiate P-I/IIa Study with BI-1206 in Combination with

Shots: In July’2019, Bioinvent reports the FDA’s acceptance of its IND application of BI-1206 + Keytruda combination therapy based on the preclinical data demonstrating that BI-1206 enhances anti-tumor immune responses in patients with solid tumors BioInvent will evaluate the combination therapy in P-I/IIa study in patients with an advanced solid tumor, prior treated with anti-PD1 […]Read More